CervoMed (NASDAQ: CRVO) — Perfil da empresa, notícias e dados financeiros
CervoMed innovates medical solutions for neurological disorders with a focus on patient care and outcomes.
CervoMed
CervoMed (NASDAQ:CRVO) is a dynamic healthcare enterprise dedicated to innovating medical solutions for neurological disorders. The company operates through a wide array of products, including diagnostic equipment, therapeutic devices, and digital health platforms, aimed at enhancing patient care and outcomes in neurology. CervoMed is deeply invested in research and development, with ongoing projects focused on pioneering treatments for conditions such as epilepsy, Parkinson's disease, and migraines. Their objective is to improve the quality of life for patients living with neurologic conditions through advanced, accessible healthcare technologies. Passionately driven by a commitment to excellence and care, CervoMed continues to push the boundaries of medical science to meet the evolving needs of patients and healthcare providers worldwide.
Resumo
Operações
Produtos e/ou serviços de CervoMed
- Advanced Neurostimulation Devices for pain management, utilizing cutting-edge technology to offer non-invasive treatment options.
- Portable EEG Systems designed for real-time brain activity monitoring, enabling efficient diagnostics and research.
- Customized Neurofeedback Programs, offering tailored solutions for cognitive enhancement and rehabilitation.
- Telemedicine Services for neurological consultations, providing accessible care to patients remotely.
- Neuro-enhancement Devices, focused on improving cognitive functions and mental health through non-invasive therapies.
- Clinical Research Services, contributing to the development of innovative neurological treatment methodologies and devices.
equipe executiva do CervoMed
- John J. AlamCo-Founder, CEO, President & Director
- Sylvie L. GregoireCo-Founder & Director
- William Robert ElderCFO, General Counsel & Corporate Secretary
- Kelly BlackburnExecutive Vice President of Clinical Development
- Marinus VerwijsExecutive Vice President of Technical Operations
- Mark A. De RoschExecutive VP of Regulatory, Government Affairs & Program Management
- Claudia OrdonezSenior Vice President of Medical Science
- Matthew WintonChief Commercial & Business Officer
Últimas notícias sobre a CervoMed
CervoMed presents neflamapimod trial data
United StatesCervoMed selects 50 mg Phase 3 dose
United StatesCervoMed completes Phase 2a trial enrollment for rare frontotemporal dementia candidate
United StatesCervoMed secures patent for neflamapimod
United StatesCervoMed reports progress on Phase 3 dementia trial infrastructure alongside Q1 results
United StatesCervoMed finalizes Phase 3 design for Lewy Body Dementia amid tight cash runway
United States
Principais indicadores financeiros
Resultados divulgados pela CervoMed, em USD.
- Cap. de mercado
- 33,4 mi
- Receita (TTM)
- 331,3 mil
- P/L
- —
- LPA (diluído, TTM)
- -3.2
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 4 mi | -28,3 mi | -27 mi | |
| 9,7 mi | -18,2 mi | -16,3 mi | |
| 7,1 mi | -7,8 mi | -2,2 mi | |
| 0 | -16 mi | -15,6 mi |